Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Recurrent or Primary Resistant FSGS
NCT00550342Phase 2Withdrawn
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in focal segmental glomerulosclerosis (FSGS), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start Jan 2008; status: withdrawn.
02
Drugs
rituximab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT00550342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550342.